IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα

Outcomes for patients diagnosed with the bone cancer osteosarcoma have not improved significantly in the last four decades. Only around 60% of patients and about a quarter of those with metastatic disease survive for more than five years. Although DNA-damaging chemotherapy drugs can be effective, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Shekhar, Tanmay M., Miles, Mark A., Gupte, Ankita, Taylor, Scott, Tascone, Brianna, Walkley, Carl R., Hawkins, Christine J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085125/
https://www.ncbi.nlm.nih.gov/pubmed/27129149
http://dx.doi.org/10.18632/oncotarget.8980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085125/
https://www.ncbi.nlm.nih.gov/pubmed/27129149
http://dx.doi.org/10.18632/oncotarget.8980

Ejemplares similares